We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Simple Blood Test Can Detect Injury and Mild Concussion

By LabMedica International staff writers
Posted on 25 Apr 2016
A simple blood has detected evidence of concussions in patients up to seven days after their injury, which could greatly expand the window for diagnosing concussions, especially in patients who experience a delayed onset of symptoms.

Almost all concussions in children are diagnosed only by symptoms, which are either observed, like vomiting or loss of balance, or symptoms reported by the child, like blurred vision or headache and neither scenario gives doctors and objective way to determine the severity of the injury.

Investigators at the Orlando Regional Medical Center (Orlando, FL, USA) enrolled adult trauma patients seen at a level I trauma center from March 1, 2010, to March 5, 2014 in a prospective cohort study. More...
A total of 1,831 blood samples were drawn over seven days from 584 patients, mean age, 40 ±16 years; and 62.0% were male. Repeated blood sampling was conducted at 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, and 180 hours after injury.

The biomarkers glial fibrillary acidic protein (GFAP) and ubiquitin C- terminal hydrolase L1 (UCH-L1) were measured. These proteins are found in glial cells, which surround neurons in the brain, and when an injury occurs, the GFAP are released. What makes them unique is that they pass the blood-brain barrier and enter the bloodstream, making them easy to detect with this particular test. Both GFAP and UCH-L1 were detectible within one hour of injury. GFAP peaked at 20 hours after injury and slowly declined over 72 hours. UCH-L1 rose rapidly and peaked at eight hours after injury and declined rapidly over 48 hours. Over the course of one week, GFAP demonstrated a diagnostic range of areas under the curve for detecting mild to moderate traumatic brain injury (MMTBI) of 0.73 to 0.94, and UCH-L1 demonstrated a diagnostic range of 0.30. For distinguishing patients with and without a neurosurgical intervention, the range for GFAP was 0.91 to 1.00 and the range for UCH-L1 was 0.50 to 0.92.

Linda Papa, MD, MSC, an emergency medicine physician, and lead author of the study, said, “This blood test could ultimately change the way we diagnose concussions, not only in children, but in anyone who sustains a head injury. We have so many diagnostic blood tests for different parts of the body, like the heart, liver and kidneys, but there has never been a reliable blood test to identify trauma in the brain. We think this test could change that.” The study was published on March 28, 2016, in the journal JAMA Neurology.

Related Links:
Orlando Regional Medical Center


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.